GLP1_NEW

PEG-loxenatide injection

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

PEGYLA_SC

Trials: 1
Participants in these arms: 189

Doses in this pooled treatment

PEG-loxenatide 25 µg injection once weekly
PEG-loxenatide 50 µg injection once weekly
PEG-loxenatide 75 µg injection once weekly
PEG-loxenatide 150 µg injection once weekly
PEG-loxenatide 200 µg injection once weekly

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Type 2 diabetes (adults)	Level 2 or 3 hypoglycemia (participants)	longest follow-up	Placebo	HR 0.39 (0.00 to 27.27)	0.45

Trials

NCT03520972
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of Twelve Once-weekly Subcutaneous Doses of PB-119 in Drug-naïve Subjects With Type 2 Diabetes Mellitus
2018 · 251 randomized · 12 weeks